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Abstract
p21-activated kinases (PAKs) act downstream of Rho-family GTPase and are linked to steps in both
cancer initiation and progression. There are six mammalian PAK isoforms that are divided into two
groups, and for different reasons both groups are attractive targets for cancer therapy. We describe
the background and recent development of a PAK inhibitor, PF-3758309, which exhibits relatively
good selectivity and high potency for PAKs. Experiments using PF-3758309 confirm that inhibiting
PAK is a beneficial strategy to combat some tumors, and this activity is likely related to modulation of
both cell proliferation and survival. The genetic loss of NF2 (neurofibromatosis type 2) leading to
increased cell proliferation through a Ras-Rac-PAK pathway may represent a good test system to
analyze this new PAK inhibitor.
Introduction and context
Rho-family GTPases signal through a variety of well-
studied ‘effector’ protein kinases (reviewed in [1]). The
p21-activated kinases (PAKs) contribute to cell cycle
progression and the plasticity of the actin cytoskeleton
and thus can contribute to a number of steps of cancer
initiation and progression [2]. The mammalian PAK
kinases fall into two distinct subgroups based on distinct
catalytic and regulatory domain homology (Figure 1).
Mammalian PAK1, PAK2, and PAK3 comprise the better-
understood group I PAKs that are activated by Rac1 and
Cdc42 and can be purified with a Rac1 and the guanine
nucleotide exchange factor (GEF) termed PIX (PAK-
interacting exchange factor) [3]. In contrast, PAK4, PAK5,
andPAK6(groupII)arenotactivatedbyCdc42bindingto
the CRIB (Cdc42/Rac interaction and binding) region [4].
PAK1 is highly expressed in the brain and promotes
synaptic plasticity [5]. It is notable that both PAK1 and
the PIX-associated GIT1 protein [6] co-localize with
huntingtin inclusions and that constitutively active PAK1
enhances the huntingtin aggregation [7]. The potential
role of PAKs in cancer progression was recently reviewed
[8]. The group 1 PAKs may be oncogenic only in specific
backgrounds such as with loss of NF2 (neurofibroma-
tosis type 2) [9]. Inhibition of PAK could be beneficial in
immune systems in which PAK1
−/− macrophages have an
attenuated ERK (extracellular signal-regulated kinase)
response [10]. There is general evidence for misregulated
PAK4 in human tumor cell lines [11] and PAK5 somatic
mutations as a cancer ‘driver’ [12]. The PAK4 locus is
present on an amplicon associated with colorectal and
pancreatic cancers [13,14].
Experiments involving upregulation or downregulation
of PAK kinase activity are the basis for most of our
current understanding of the PAK kinases. It is therefore
unfortunate that awidely used activation loop, phospho-
mimetic mutant PAK1 (T423E), is actually not active
in vivo [15].
Previous strategies to inhibit PAKs
Aside from siRNA (short interfering RNA)-mediated
knockdown of one or multiple PAK isoforms, most
credible information regarding PAK function has been
gleaned through the use of the PAK1 auto-inhibitory
domain (AID), which exhibits a dissociation constant
(Ki) of approximately 90 nM toward PAK1 activation
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does exert effects independent of PAK1 inhibition [17]:
some rationale for this off-target effect of PAK1 AID
comes from the observation that it avidly binds fragile-X
proteins [18]. Fortunately, the PAK2 AID does not have
this unwanted side effect as a genetically encoded GST
fusion protein (Zhao Z-S, Manser E, unpublished
observations). There has been significant interest in
development of drugs against PAKs as therapeutic agents,
and these would greatly aid in elucidating the biology
of PAKs.
Major recent advances
Inhibitor of group I PAKs
The only reported PAK inhibitor for this group in which
selectivity has been assessed against a wide spectrum of
kinases is IPA-3 (p21-activated kinase inhibitor 3). This
small-molecule PAK inhibitor was developed from a
screen designed to detect an inhibition of Cdc42-
mediated PAK1 activation rather than kinase activity
[19]. This allosteric inhibitor of PAK kinase activation
does not target the ATP-binding pocket but rather the
regulatory interface where Cdc42 or Rac1 binds PAK
(Figure 1). The mechanism of action of IPA-3 involves
binding and covalent attachment to the PAK1 regulatory
domain [20], but this reaction is reversible. Since
the compound contains a disulphide bond, it is
inactivated inside cells, and this makes it unsuitable for
therapeutic use.
Inhibitor of group II PAKs
A recent groundbreaking paper characterizes an orally
administrable compound developed by Pfizer Inc. (New
York, NY, USA), termed PF-3758309 [21], which exhibits
potent binding and inhibition (Ki of ~5-15 nM) of PAKs
in an ATP-competitive manner (Figure 1). PF-3758309
was profiled for its growth-inhibitory activity in a panel
of 92 tumor cell lines, half of which exhibited IC50
(inhibitory concentration for 50% of maximal effect)
values of less than 10 nM. Pathway profiling of this
inhibitor has suggested links to apoptosis and the
cytoskeleton as expected for PAK4 [22]. In all, this
paper gives support to the notion of PAKs as therapeutic
targets in cancer. However, PF-3758309 acts on both
group I and II PAKs as well as AMPK (AMP-dependent
kinase) and RSK (ribosomal S6 kinase) at nanomolar
concentrations. The in vivo inhibition of GEF-H1
phosphorylation at Ser-810 indicates PAK4 or PAK1
inhibition (or both) [23]. Measured in vitro, the Ki
toward PAK4 is approximately 19 nM whereas the value
quoted for PAK2 is 10 times higher (~190 nM) and that
for PAK1 is approximately 14 nM. Given that the active
sites of the group I PAK kinases are essentially identical,
this is unexpected.
Future directions
The data on PF-3758309 as described [21] indicate that
this drug is an excellent inhibitor of both group I and II
PAKs. The two PAK classes can have somewhat different
substrate specificities in vitro [24], although thus far we
are not aware of any that are validated in vivo. Comparing
the effects of IPA-3 versus PF-3758309 would allow one
to differentiate between these targets. With respect to
genuine isoform-specific PAK inhibitors, targeting the
kinase domain would seem to be problematic. Since
PAK1 knockout mice have only minor abnormalities in
the central nervous system and immune systems [5,25],
compensation in any case between PAK1 and PAK2 is
likely in most tissues. The complication with comparing
knockout models with inhibitors is that PAKs have
kinase-independent activities [26].
At present, PAK-oriented therapy seems obvious for
oncology in which PAKs contribute to progression and
persistence of the disease; the xenograft models in mice
suggest that PF-3758309 does not impact animal
Figure 1. Schematic diagram of the regions targeted by various
p21-activated kinase (PAK) inhibitors
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Both group I and group II PAKs contain related catalytic and Cdc42/Rac
interaction and binding (CRIB) domains. PAK1, PAK2, and PAK3 are
inhibited in trans via an auto-inhibitory domain (AID), which when
expressed as a glutathione S-transferase (GST) fusion protein can effectively
inhibit the kinase [16]. The PAK1-, PAK2-, and PAK3-binding partner PIX
(PAK-interacting exchange factor) interacts via a highly unusual SH3-
interacting region [3]. The small-molecule inhibitor IPA-3 (p21-activated
kinase inhibitor 3) is a symmetric dimer joined by a disulphide bond [19]
which targets the CRIB region. The structure of PF-3758309 is shown for
reference; PF-3758309 binds the ATP-binding pocket of PAKs as revealed
by the X-ray structure of the PAK4-PF-3758309 complex [21].
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potential of PAK inhibitors such as PF-3758309 for
treatment of NF2 patients is quite exciting. NF2 is usually
diagnosed in young adults by tinnitus or imbalance and
is characterized by bilateral vestibular schwannomas
growing on the eighth cranial nerve. The NF2 gene
product termed merlin is thought to be activated by PAK
or PKA (protein kinase A) phosphorylation at Ser-518.
Merlin is proposed to negatively regulate PAK1 [27], and
thus primary schwannoma samples derived from NF2
patients have elevated PAK1 activity [9]. IPA-3 blocks
inappropriate PAK2 activation and associated PIX-
mediated events in schwannoma cells [28].
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